Assessing HTA methodology to evaluate the cost-effectiveness of gene therapies and value frameworks for evaluation and policy making for cell and gene therapies.

Project Member(s): De Abreu Lourenco, R.

Funding or Partner Organisation: AstraZeneca Pharmaceuticals LP (AstraZeneca Pharmaceuticals Contract research)
AstraZeneca Pharmaceuticals LP (AstraZeneca Pharmaceuticals Contract research)

Start year: 2023

Summary: Assessing HTA methodology to evaluate the cost-effectiveness of gene therapies and value frameworks for evaluation and policy making for cell and gene therapies. This proposal relates to the following specific components of the project as part of the overall PhD research program: (1) conduct of qualitative research with patient and carers on their experiences of treatment costs associated with inherited retinal diseases; and (2) a survey of industry, Government and patient stakeholders on their experience associated with accessing gene therapies for inherited retinal diseases. The student will submit articles on each of the above projects (one each) to relevant journals, as well as prepare a final thesis for submission (as submission by publication), including an overarching introductory and discussion chapter, and research papers prepared during the course of the PhD candidature addressing the research question.

FOR Codes: Health policy evaluation, Health economics

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.